Nautilus Biotechnology Reports Third Quarter 2025 Financial Results

Core Insights - Nautilus Biotechnology, Inc. reported financial results for Q3 2025, highlighting progress towards commercialization of its proteome analysis platform by late 2026 [1][3]. Financial Performance - Operating expenses for Q3 2025 were $15.5 million, a 19% decrease from $19.1 million in Q3 2024, attributed to operational efficiencies and reduced development costs [4]. - The net loss for Q3 2025 was $13.6 million, improved from a net loss of $16.4 million in the same period last year [4]. - As of September 30, 2025, cash, cash equivalents, and investments totaled $168.5 million [5]. Business Developments - The company is focused on launching an early access program for Tau proteoforms in the first half of 2026, which is a critical step towards full commercial availability [3][9]. - Continued progress was made in processing Tau proteoform samples, supporting product validation and increasing publications [9]. - Development of a new broadscale assay format is underway, aimed at supporting the commercial launch planned for late 2026 [9].